The plasmaMATCH clinical trial aiming to evaluate clinical activity of targeted treatments in patients with advanced breast cancer where the targetable mutation is identified through circulating tumour DNA screening. The results were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS). Twenty-one patients with HER2 mutation were enrolled and 20 patients were evaluable. They received either neratinib monotherapy (for patients with hormone receptor negative disease) or neratinib in combination with fulvestrant (for patients with hormone receptor positive disease). In this cohort, most of the patients had hormone receptor positive breast cancer (86%) and received prior chemotherapy for metastatic disease (86%). The results showed that 5 patients (25%) had objective response and the median progression-free survival was 4.5 months. Based on this data, in heavily pretreated advanced breast cancer with HER2 mutation, neratinib ± fulvestrant could be a new treatment option.
Wardley. SABCS 2019. Abstr P1-19-07.